Pathstone Family Office
TAK icon

Pathstone Family Office’s Takeda Pharmaceutical TAK Stock Holding History

Pathstone Family Office’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$203K Buy
+13,094
New +$203K ﹤0.01% 1515
2023
Q1 		– Sell
-22,211
Closed -$115K – 1358
2022
Q4 		$115K Buy
+22,211
New +$310K ﹤0.01% 1161

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pathstone Family Office's TAK Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Takeda Pharmaceutical (TAK) in Q3 2023: 13,094 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #1515 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in TAK as recently as Q4 2022.

Pathstone Family Office first reported a position in TAK in Q4 2022 and has held it in 2 quarters since. 313 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

  • Pathstone Family Office held 13,094 shares of Takeda Pharmaceutical worth $203K as of Q3 2023.
  • Takeda Pharmaceutical was a new Pathstone Family Office position in Q3 2023.
  • Takeda Pharmaceutical made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1515 holding.
  • Pathstone Family Office first reported a position in Takeda Pharmaceutical in Q4 2022 and has held it in 2 quarters since.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.